Complement receptor one (CR1) is a ligand for the rosetting of Plasmodium falciparum infected red cells with uninfected cells. Since CR1 exhibits three known polymorphisms, we studied European-Americans (n = 112) and African-Americans (n = 330) and Malians (n = 158) to determine if genetic differences existed in an area endemic for malaria that could offer a survival advantage. The frequencies of Knops blood group phenotypes McC(b+) and Sl(a−) were greatly increased in Africans vs Europeans. Although the frequency of McC(b+) was similar between Africans from the USA or Mali, the Sl(a−) phenotype was significantly higher in Mali (39% vs 65%, respectively). There was an increased frequency of the largest size (250 kD) of CR1 in Mali, but this did not differ significantly from the USA (P = 0.09). Both cohorts of Africans had higher expression of red cell CR1 than European-Americans but this showed little difference between the USA and Mali groups. Thus, the most important CR1 polymorphism relevant to rosetting of malaria infected cells appears to be the Knops blood group. Genes and Immunity (2000) 1, 325-329.
Introduction
Complement receptor one (CR1) is a glycoprotein found on most peripheral blood cells including red blood cells. Its major function is the adherence to and removal of immune complexes, however, it also has complement regulatory activity. 1 Human CR1 exhibits three known polymorphisms including: molecular weight (structural), level of red cell expression, and the Knops blood group. There are four molecular weight variants that differ in size by approximately 30 kD yet possess similar Factor I co-factor activity. 2 The molecular weights for these variants determined by SDS-PAGE using non-reduced conditions are: CR1*1 = 190 kD, CR1*2 = 220 kD, CR1*3 = 160 kD and CR*4 = 250 kD. Holers et al 3 showed that the difference in molecular weight was due to differing sizes of mRNA and not post-translational processing. The CR1 size polymorphism is not unique to red cells but also exists on other cells such as neutrophils and eosinophils.
The number of CR1 copies on erythrocytes (E-CR1) can vary as much as ten-fold between individuals. In European-Americans, a Hind II RFLP has been identified which correlates with high (H allele) or low (L allele) expression. 4 However, a similar correlation was not found in a study of African-Americans. 5 Although there appears to be genetic regulation of E-CR1, low CR1 copy numbers can also be an acquired phenomenon in malignant and inflammatory disorders. [6] [7] [8] In 1991, two groups independently identified the Knops blood group system on CR1. 9, 10 It has been shown to be independent from the other known CR1 polymorphisms, ie, molecular weight or red cell expression. The Knops blood group system began with the description of anti-Knops (Kn a ), in a transfused Caucasian woman. 12 as they lack complete biochemical and genetic studies for inclusion in the system. To date, none have been identified at the molecular level. The serological null phenotype is known as the 'Helgeson phenotype' which results from very low CR1 copy numbers on the red cell. 13 The importance of CR1 in malaria became evident when Rowe et al 14 reported that CR1 was a ligand to which the parasite receptor, ie, PfEMP-1, bound when Plasmodium falciparum infected red cells rosetted with uninfected cells. Red cells with low CR1 copy numbers did not rosette or rosetted poorly. In addition, red cells that typed as Sl(a−) formed fewer rosettes than Sl(a+) red cells. In an earlier study, 15 the Sl(a−) phenotype was found with an increased frequency among AfricanAmericans compared to European-Americans. Since rosetting had previously been correlated with severity of disease, 16 Rowe et al 14 suggested that the Sl a mutation might protect against severe malaria in African derived populations. Thus, we studied a population in West 
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Africa to determine whether any of the CR1 polymorphisms were more frequent in Africans as compared to African or European-Americans.
Results

CR1 molecular weight
The gene frequencies for the four molecular weight variants of CR1 are shown in Table 1 . The gene frequencies for CR1*1, CR1*2 and CR1*3 occurred with the same frequency in Africa as in the USA. Of note, the CR1*3 allele (160 kD) has been found more often in AfricanAmericans than any other population tested. 17 The largest size of CR1 (250 kD, CR1*4) was found in 4.6% of Malians as compared to 1% of African-Americans (P = 0.09). We also noted that not all CR1 structural variants were equally expressed ( Figure 1 ) but this differential expression did not correlate with any particular CR1 size allele.
E-CR1 expression E-CR1 was quantified in 65 European-Americans, 60
African-Americans and 158 Malians. In both African- derived groups, the average levels of E-CR1 were higher than in White subjects ( Table 2 ). The Mali data had a somewhat broader range of values (s.d. = 173) when compared to the other two groups (s.d. = 125 and 130).
Knops blood group
The results for the Knops blood grouping are shown in Table 3 . Although the McC b antigen is rare among European-Americans it was found in ෂ40% of both African-Americans and West Africans from Mali. Of the 11 families studied, three were informative for the McCoy locus ( Figure 2 ). In families three and 20 the mother carries the McC(b+) haplotype which is passed to the child while in family eight the paternal haplotype is McC(b+). These families provide evidence that McC b is 
Discussion
The different CR1 molecular weight variants are the products of four different mRNA rather than varying glycosylation. 3 It had been proposed that they arose through the duplication and deletion of long homologous regions of a primordial CR1 gene. Wong et al 18 showed that the smaller form of CR1 (FЈ or CR1*3) had a reduced capacity to bind immune complexes (ICs). It had been reported that this small form of CR1 was a genetic risk factor for SLE; 19 however, other studies have found no difference in the structural allele frequencies between SLE patients and matched controls. 20 We found that CR1*3 occurred with similar gene frequencies in both African-Americans and Malians. Presumably, the larger forms (S or CR1*2 and CR1*4) which have more C3b-binding sites would have an enhanced ability to remove ICs. Although SLE is uncommon in Mali (D. Diallo, unpublished data), it is unknown whether the CR1 structural alleles are protective genetic factors in this population. The increased frequency of the larger forms of CR1 in the West African population may be in response to infectious diseases including viruses, bacteria and parasites.
In addition to the size variant, the number or CR1 molecules on the red cell can affect its ability to bind ICs. We found that the average E-CR1 among Africans was higher than European-Americans. In the latter group, the expression polymorphism is linked to a Hind III restriction fragment length polymorphism located in an intronic region of the CR1 gene. 4 A recent report by Herrera et al 5 suggests that there is little correlation between this RFLP and CR1 expression in African-American donors. The actual genetic elements controlling red cell expression have yet to be identified in either population. Screening of 2091 unrelated blood donors of unknown race using the original anti-Kn a yielded only four Kn(a−) individuals. 11 Molthan 21 found 1.2% of random AfricanAmericans to be Kn(a−). In Mali, two donors typed as Kn(a−), however, one had the Helgeson, ie, null phenotype, and can be considered a false negative. The second Mali donor was also negative for the low frequency allele Kn b suggesting the presence of a third allele or an amorph. Molthan 15 had previously speculated that a third allele might be present at this locus among African-Americans. Molthan 14 for the rosetting studies were McC(b−), therefore, the effect of this mutation on rosetting is unknown at this time.
Of the Malian families obtained for the study of inheritance, we found three to be informative for the McCoy antigens (Figure 2) 15 Molthan reported that 49% of the 371 random African-American donors from Pennsylvania that she tested were McC c −, ie, Sl(a−), but in our study of African-Americans (from Houston, TX, and Birmingham, AL, USA) the frequency was only 39%. This differed significantly from the Malian donors where 70% were Sl(a−). Furthermore, less than 1% of European-Americans have the Sl(a−) phenotype. If indeed the Sl(a−) mutation protects patients from severe malaria, then one would expect an increased frequency of the Sl(a−) phenotype in a pure African population. Certainly, there is precedence for these observations within the Duffy (Fy) blood group. The Fy(a−b−) phenotype occurs in 60% of AfricanAmericans but 100% of West African populations; red cells with this type are unable to be invaded by Plasmodium vivax. 23 The CR1 protein appears to play a major role in the rosetting of Plasmodium falciparum infected red cells to uninfected cells. This phenomenon has been correlated with the increased severity and mortality of falciparum malaria. Thus, it might be expected that several mutations would occur in this gene to impede the parasite. Our data suggest that the blood group mutation, Sl(a−) may offer a protective advantage from severe malaria. However, since these are the first ever studies of CR1 polymorphisms in Africa, further testing of other African populations needs to be performed.
Materials and methods
The appropriate Human Use Committees approved the research protocol at both the University of Texas Health Science Center and the University of Mali. After obtaining consent, ACD blood samples were drawn from 112 White controls, 330 random Black controls from across the USA and 158 donors from three sites in Mali. Tienequebougou is a small village of Bambaran ethnicity, Bamako is a large metropolitan area having mixed ethnicity and Bancoumana is a village primarily of Malinke ethnicity. The Malian cohort included 11 families that were studied for inheritance patterns but the related donors (n = 19) were excluded from gene frequency calculations. Red cell ghosts were immediately prepared on site and kept frozen at −80°C until tested and serological studies were performed within 48 h.
Determination of molecular weight
Red cell ghosts were prepared using hypotonic lysis and the membrane proteins were solulibilized in SDS. The proteins were separated by SDS-polyacrylamide gel electrophoresis using a 3% stacking gel and a 5% separating gel at 150V for 1 h. The proteins were electrophoretically transferred to nylon membrane and blocked overnight in 5% milk powder/PBS. The blots were incubated for 1 h at 24°C with a monoclonal anti-CR1 (J3D3) then washed three times in PBS/Tween. This was followed by a 1-h incubation with goat anti-mouse IgG conjugated to horseradish peroxidase. The bands were visualized using a chemiluminescence method (ECL, Amersham, USA) and compared to known molecular weight markers.
Determination of E-CR1 copy number E-CR1 copy number was determined using modified version of previously described ELISA. 13 Briefly, membrane ghosts were solubilized in NP 40 and 100 l was added to a microtiter plate previously coated with anti-CR1 (J3D3) and blocked with 0.05% BSA. The plates were incubated for 2 h at 24°C and washed in PBS/0.05% Tween. Next, 100 l of biotinylated anti-CR1 (E11) was added, incubated for 2 h at 24°C and washed as before. Finally, 100 l of strepavidin were added and the plates incubated at 24°C for 20 mins. followed by three washes. Color development utilized a hydrogen peroxide: tetramethyl benzidine substrate (Pierce Chemical, USA). The reaction was stopped with 0.5 M H 2 SO 4 and the color read at 450 nm in a microtiter-plate spectrophotometer. The E-CR1 number was extrapolated from a standard curve using a donor of known copy number (determined during the VII th International Complement Genetics Workshop).
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Determination of Knops blood group phenotypes Anti-Kn a , -McC a , -McC b and -Sl a were obtained from multiply transfused patients who had been immunized through transfusion to the CR1 polymorphisms. These antibodies were initially identified by AABB Reference Laboratories and confirmed by us. The same antisera were used to type the samples in this study. When possible ABO compatible sera were used and for all others sera absorbed free of A and B isoagglutinins were utilized. Test red blood cells were washed and re-suspended to a 4% concentration using PBS. Fifty microliters of the cell suspension was added to 75 l of each antibody specificity, incubated 1 h at 37°C followed by an antiglobulin test using rabbit polyspecific antisera. The results were read macroscopically using an agglutination viewer and scored on a scale of 0-4+.
